HUP9900730A2 - Olvadékextrudálással előállított szilárd ciklodextrinkeverék - Google Patents

Olvadékextrudálással előállított szilárd ciklodextrinkeverék

Info

Publication number
HUP9900730A2
HUP9900730A2 HU9900730A HUP9900730A HUP9900730A2 HU P9900730 A2 HUP9900730 A2 HU P9900730A2 HU 9900730 A HU9900730 A HU 9900730A HU P9900730 A HUP9900730 A HU P9900730A HU P9900730 A2 HUP9900730 A2 HU P9900730A2
Authority
HU
Hungary
Prior art keywords
extrusion
prepared via
solid mixtures
via melt
cyclodextrins prepared
Prior art date
Application number
HU9900730A
Other languages
English (en)
Inventor
Lieven Elvire Colette Baert
Jozef Peeters
Geert Verreck
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26139823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9900730(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HUP9900730A2 publication Critical patent/HUP9900730A2/hu
Publication of HUP9900730A3 publication Critical patent/HUP9900730A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgya eljárás szilárd keverék előállítására, amely egyvagy több ciklődextrint és egy vagy több hatóanyagőt tartalmaz őlymódőn, hőgy az eljárás egy őlvadékextrűdálási lépést tartalmaz,melynek sőrán a hatóanyagőt beágyazzák a ciklődextrinhőrdőzóba. Atalálmány kiterjed a fenti eljárással előállítható szilárd keverékre,az ilyen őlvadékextrűdátűmőt tartalmazó gyógyszerkészítményre, ésannak előállítására. ŕ
HU9900730A 1995-11-23 1996-11-20 Solid mixtures of cyclodextrins prepared via melt-extrusion HUP9900730A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203219 1995-11-23
US09/081,808 US6365188B1 (en) 1995-11-23 1998-05-20 Solid mixtures of cyclodextrins prepared via meltextrusion

Publications (2)

Publication Number Publication Date
HUP9900730A2 true HUP9900730A2 (hu) 1999-07-28
HUP9900730A3 HUP9900730A3 (en) 2001-04-28

Family

ID=26139823

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900730A HUP9900730A3 (en) 1995-11-23 1996-11-20 Solid mixtures of cyclodextrins prepared via melt-extrusion

Country Status (16)

Country Link
US (1) US6365188B1 (hu)
EP (1) EP0862463A1 (hu)
JP (1) JP3310299B2 (hu)
CN (1) CN1198655C (hu)
AU (1) AU725204B2 (hu)
BR (1) BR9611562A (hu)
CZ (1) CZ154398A3 (hu)
HU (1) HUP9900730A3 (hu)
IL (1) IL123654A (hu)
NO (1) NO981078L (hu)
NZ (1) NZ322907A (hu)
PL (1) PL189122B1 (hu)
SK (1) SK67298A3 (hu)
TR (1) TR199800729T2 (hu)
WO (1) WO1997018839A1 (hu)
ZA (1) ZA969831B (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ322907A (en) * 1995-11-23 1998-12-23 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
DE59803468D1 (de) 1997-11-28 2002-04-25 Knoll Ag Verfahren zur herstellung von lösungsmittelfreien nicht-kristallinen biologisch aktiven substanzen
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
HU230394B1 (hu) 1998-11-10 2016-04-28 Janssen Pharmaceutica N.V. HIV-vírus szaporodását gátló pirimidin-származékok
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
DE19911097A1 (de) * 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
BR0009176A (pt) 1999-03-24 2001-12-18 Fmc Corp Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular
SK15772001A3 (sk) 1999-05-04 2002-12-03 Janssen Pharmaceutica N. V. Antifungálne étery
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
ES2317889T3 (es) 2000-03-01 2009-05-01 Janssen Pharmaceutica Nv Derivados de tiazolilo 2,4-disustituido.
US6835717B2 (en) 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
ITRN20000051A1 (it) 2000-12-22 2002-06-22 Ascor Chimici Srl Metodo e apparecchiatura per formare sferule composite contenenti principi attivi del tipo farmaceutico e/o integratori alimentari o cosmeti
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2002324045C1 (en) 2001-08-13 2008-05-29 Janssen Pharmaceutica N.V. 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
BR0307599A (pt) 2002-03-13 2005-02-01 Janssen Pharmaceutica Nv Derivados de sulfonilamino como inibidores de histona deacetilase
IL164007A0 (en) 2002-03-13 2005-12-18 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase
CN102702111B (zh) 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
ES2311146T3 (es) 2003-02-07 2009-02-01 Janssen Pharmaceutica Nv 1,2,4-triazinas que inhiben el vih.
BRPI0407329A (pt) 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevenção de infecção de hiv
CL2004000306A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
CN101912615B (zh) * 2003-03-28 2013-03-27 阿莱斯贸易有限公司 用于改善的经口和透粘膜输送的克拉屈滨制剂
ATE476177T1 (de) * 2003-03-28 2010-08-15 Ares Trading Sa Orale zubereitungen enthaltend cladribin
ATE500254T1 (de) 2003-09-25 2011-03-15 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
MX2007001120A (es) 2004-07-28 2007-03-15 Janssen Pharmaceutica Nv Derivados de indolil alquil sustituidos como nuevos inhibidores de la histona desacetilasa.
US7923554B2 (en) 2004-08-10 2011-04-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
AU2005288866B2 (en) 2004-09-30 2012-07-26 Janssen Sciences Ireland Uc HIV inhibiting 5-substituted pyrimidines
CA2577467C (en) 2004-09-30 2013-05-28 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
US8153640B2 (en) 2004-10-29 2012-04-10 Tibotec Pharmaceuticals Ltd. HIV inhibiting bicyclic pyrimdine derivatives
WO2006079656A1 (en) 2005-01-27 2006-08-03 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives
DK1858861T3 (da) 2005-03-04 2010-11-08 Tibotec Pharm Ltd HIV-inhiberende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidiner
DK1912626T3 (en) * 2005-08-08 2016-08-01 Abbvie Deutschland Dosage forms with improved bioavailability
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
BRPI0709266B8 (pt) 2006-03-30 2021-05-25 Janssen R & D Ireland 5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende
JP5078986B2 (ja) 2006-03-30 2012-11-21 テイボテク・フアーマシユーチカルズ Ｈｉｖを阻害する５−アミド置換されたピリミジン
EP2781510B1 (en) 2006-12-29 2016-12-14 Janssen Sciences Ireland UC Hiv inhibiting 5,6-substituted pyrimidines
BRPI0720858B8 (pt) 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
EP2280681A1 (en) * 2008-04-30 2011-02-09 Novartis AG Continuous process for making pharmaceutical compositions
WO2010128359A1 (en) 2009-05-07 2010-11-11 Gea Pharma Systems Limited Tablet production module and method for continuous production of tablets
US20120148678A1 (en) 2010-12-08 2012-06-14 Advanced Technologies And Regenerative Medicine, Llc. Sustained release of poorly water soluble active compounds
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CN107441504A (zh) * 2017-09-06 2017-12-08 广州中医药大学 番茄红素包合物及其制备方法及番茄红素包合物片剂、胶囊和颗粒
CN110898015A (zh) * 2019-12-31 2020-03-24 上海汉维生物医药科技有限公司 一种伊曲康唑制剂的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152765A (ja) * 1984-12-27 1986-07-11 Nippon Ekishiyou Kk シクロデキストリン類で包接された化合物を含有した合成樹脂製品及びその製造方法
US5009900A (en) * 1989-10-02 1991-04-23 Nabisco Brands, Inc. Glassy matrices containing volatile and/or labile components, and processes for preparation and use thereof
KR100291361B1 (ko) * 1992-10-14 2001-09-17 니뽄 신야쿠 가부시키가이샤 결정상태의전이방법
AU5376994A (en) * 1992-11-10 1994-06-08 Nippon Shinyaku Co. Ltd. Enclosure compound manufacturing method
FR2705677B1 (fr) * 1993-05-28 1995-08-11 Roquette Freres Micro-granules obtenus par extrusion-sphéronisation contenant une cyclodextrine.
NZ322907A (en) * 1995-11-23 1998-12-23 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
KR100331529B1 (ko) 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
BR9611562A (pt) 1999-03-02
WO1997018839A1 (en) 1997-05-29
HUP9900730A3 (en) 2001-04-28
NZ322907A (en) 1998-12-23
TR199800729T2 (xx) 1998-07-21
EP0862463A1 (en) 1998-09-09
PL189122B1 (pl) 2005-06-30
ZA969831B (en) 1998-05-22
SK67298A3 (en) 1998-11-04
IL123654A (en) 2001-08-08
CZ154398A3 (cs) 1998-08-12
AU725204B2 (en) 2000-10-05
NO981078L (no) 1998-05-22
IL123654A0 (en) 1998-10-30
JPH11501050A (ja) 1999-01-26
NO981078D0 (no) 1998-03-11
AU7694396A (en) 1997-06-11
PL326161A1 (en) 1998-08-31
US6365188B1 (en) 2002-04-02
JP3310299B2 (ja) 2002-08-05
CN1198655C (zh) 2005-04-27
CN1200677A (zh) 1998-12-02

Similar Documents

Publication Publication Date Title
HUP9900730A2 (hu) Olvadékextrudálással előállított szilárd ciklodextrinkeverék
HUP9801151A2 (hu) Stabilan tárolható gyógyszerformák
HUP9900983A2 (hu) Béta-laktám vegyületeket tartalmazó agglomerátumok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
DE68913977T2 (de) Polymerzusammensetzung und verfahren zur herstellung.
NO973767L (no) Biologisk nedbrytbare polymerer, fremgangsmåte for fremstilling, samt anvendelse av polymerene for fremstilling av biologisk nedbrytbare formlegemer
DE68911299T2 (de) Enzymelektrode und verfahren zur herstellung.
DE3786891D1 (de) Sehr weicher spinnvliesstoff und verfahren zur herstellung desselben.
ATA86885A (de) Verfahren zur herstellung lagerstabiler, schnellzerfallender pharmazeutischer wirkstoff-presslinge
DE69814965D1 (de) Strangpressverfahren und Strangpressvorrichtung zur Herstellung von Reifenlaufflächen
DE3770956D1 (de) Flavonglycosid, verfahren zur herstellung und pharmazeutische zusammensetzung, welche dieses produkt enthaelt.
DE68923959T2 (de) Glykosid-derivate, polymere enthaltend glykosid-derivate, verfahren zur herstellung und deren verwendung.
HUP0000279A2 (hu) Kompozíciók szilárd gyógyszeripari és élelmiszer-ipari készítmények előállításához, ilyen formázott és nem formázott készítmények, valamint eljárás ezek előállítására
DE68907447T2 (de) Geblasene, einstückige Flasche und Verfahren zur Herstellung derselben.
DE69616446T2 (de) Verfahren zur herstellung von alpha-haloketonen, alpha-halohydrinen und epoxiden
DE3785319T2 (de) Verfahren zur herstellung von polymeren aus c0 und olefinungesaettigten verbindungen.
DE69613755D1 (de) Verfahren zur Herstellung von Extrusionsdüsen
DE69634895D1 (de) Kieselsäuregel, synthetisches quarzglaspulver, geformtes quarzglas und verfahren zu deren herstellung
DE68908223T2 (de) Verfahren zur Herstellung von sehr reiner, dichter grossteiliger Kieselsäure.
DE68917457T2 (de) Deodorant und verfahren zur herstellung.
DE68904582T2 (de) Elektroakoustische membran und verfahren zur herstellung.
DE3874415D1 (de) Stranggepresster gegenstand und verfahren zur herstellung desselben.
DE68916760D1 (de) Verfahren zur Herstellung von Gamma-Lactonen.
DE69422275T2 (de) Chemopräventive verbindungen, verfahren zur herstellung und anwendungen
DE69313297T2 (de) Benzofuranone, benzodifurantrione und verfahren zur herstellung von benzodifurandionen
FI961539A0 (fi) Suulakepuristusmenetelmä, suulakepuristin ja menetSuulakepuristusmenetelmä, suulakepuristin ja menetelmällä tehty tuote elmällä tehty tuote